SRR1362464
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.420
- INFLAMMATORY_RESPONSE+0.396
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.378
- IL6_JAK_STAT3_SIGNALING+0.345
- ANGIOGENESIS+0.316
- COAGULATION+0.311
- APICAL_SURFACE+0.306
- ALLOGRAFT_REJECTION+0.304
- MYOGENESIS+0.271
- KRAS_SIGNALING_UP+0.255
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.688
- MYC_TARGETS_V1-0.677
- MYC_TARGETS_V2-0.560
- DNA_REPAIR-0.543
- UNFOLDED_PROTEIN_RESPONSE-0.504
- E2F_TARGETS-0.491
- PROTEIN_SECRETION-0.479
- MTORC1_SIGNALING-0.423
- G2M_CHECKPOINT-0.392
- FATTY_ACID_METABOLISM-0.379
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1331289 | GTEX | — | 0.967 |
| 2 | SRR615096 | GTEX | — | 0.960 |
| 3 | SRR1375616 | GTEX | — | 0.958 |
| 4 | SRR1414424 | GTEX | — | 0.957 |
| 5 | SRR598894 | GTEX | — | 0.954 |
| 6 | SRR817758 | GTEX | — | 0.953 |
| 7 | SRR820292 | GTEX | — | 0.953 |
| 8 | SRR1429957 | GTEX | — | 0.950 |
| 9 | SRR658645 | GTEX | — | 0.950 |
| 10 | SRR1394297 | GTEX | — | 0.948 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.420 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.396 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.378 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.345 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.316 | Remibrutinib | — uncovered |
| COAGULATION | 0.311 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.306 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.304 | Idelalisib | — uncovered |
| MYOGENESIS | 0.271 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.255 | Inavolisib | — uncovered |
| COMPLEMENT | 0.219 | Inavolisib | — uncovered |
| HYPOXIA | 0.206 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.181 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.165 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.145 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.135 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.117 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.107 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.083 | Inavolisib | — uncovered |